Don’t just focus on vaccines. The competition for new antibodies is accelerating

GlaxoSmithKline and vir biotechnology have officially started human trials of the new coronavirus antibody drug, which may be available in the first half of next year. This marks that the competition of antibody treatment track is becoming increasingly fierce. < / P > < p > the two companies announced on Monday that antibody therapy was directly into the mid-term clinical phase and final human trials through a study conducted last week. The trial will cover 1300 new coronavirus patients from all over the world, aiming to prevent the deterioration of mild new coronavirus. The company said preliminary conclusions could be reached by the end of the year. The novel coronavirus pneumonia and

Vir Biotechnology are the manufacturers of monoclonal antibodies, which are designed to simulate the body’s natural immune response and even prevent new crown pneumonia. Antibody therapy may provide an effective short-term treatment before the vaccine is available, especially for the elderly patients and the patients with poor physique who are also difficult to produce effect by vaccination. Other competitors at the antibody therapy track are also pushing ahead: AstraZeneca said last week that it had started human trials of a combination of the two antibodies; early data on a group of antibodies being tested by regenerant will be released in September; and Lilly will begin the final phase of its drug trials in US nursing homes this month. George scangos, CEO of vir biotechnologyde, said in an interview: “the demand for new crown antibodies may be so great that no one company can meet all the needs.”. 08/16/2020